NASDAQ:CVAC CureVac Q1 2025 Earnings Report $4.66 0.00 (0.00%) As of 09/17/2026 ProfileEarnings HistoryForecast CureVac EPS ResultsActual EPS-$0.24Consensus EPS -$0.16Beat/MissMissed by -$0.08One Year Ago EPSN/ACureVac Revenue ResultsActual Revenue$0.94 millionExpected Revenue$4.27 millionBeat/MissMissed by -$3.33 millionYoY Revenue GrowthN/ACureVac Announcement DetailsQuarterQ1 2025Date5/22/2025TimeBefore Market OpensConference Call DateTuesday, May 20, 2025Conference Call Time2:00AM ETConference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) CureVac Earnings HeadlinesCureVac sues Moderna for patent infringement over COVID-19 vaccinesApril 24, 2026 | reuters.comCureVac (NasdaqGM:CVAC) Valuation After New mRNA Pipeline Progress And Refined Capital Allocation PlanJanuary 22, 2026 | finance.yahoo.comAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly 80% afterward. He also called the housing crisis and the collapse of Bear Stearns and Lehman Brothers before they happened. Now Tilson says the day after this year's midterm elections, America enters a period of economic change unlike anything seen in decades - and most investors are unprepared.September 18 at 1:00 AM | Stansberry Research (Ad)BioNTech Completes CureVac Takeover and Updates Articles of AssociationJanuary 6, 2026 | tipranks.comBioNTech SE (BNTX) Closes the Acquisition of CureVac N.V.December 23, 2025 | insidermonkey.comBioNTech Completes CureVac Acquisition to Bolster mRNA LeadershipDecember 18, 2025 | tipranks.comSee More CureVac Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CureVac? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CureVac and other key companies, straight to your email. Email Address About CureVacCureVac (NASDAQ:CVAC) is a biopharmaceutical company focused on developing medicines and vaccines based on messenger RNA (mRNA) technology. The company’s research programs have addressed infectious diseases, oncology, and other conditions in which mRNA may be used to instruct cells to produce therapeutic proteins or stimulate an immune response. Founded in 2000 and headquartered in Tübingen, Germany, CureVac has developed proprietary mRNA design, manufacturing, and delivery technologies. Its pipeline has included vaccine candidates for infectious diseases, including COVID-19 and seasonal influenza, as well as cancer immunotherapies and protein-replacement treatments. The company has historically pursued development and commercialization through collaborations with pharmaceutical and biotechnology partners, including GSK. CureVac has conducted research and clinical development activities in Europe and the United States. Alexander Zehnder has served as the company’s chief executive officer. CureVac’s programs remain subject to clinical, regulatory, and commercial development, and the company has not established a broad portfolio of marketed products.View CureVac ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and ScaleMicron’s New 512GB Memory Module Deepens Its AI Infrastructure AdvantageThese 3 Stocks Are Drawing Insider Buyers for Very Different Reasons Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
